↓ Skip to main content

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

Overview of attention for article published in Neuropsychiatric Disease and Treatment, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Published in
Neuropsychiatric Disease and Treatment, September 2015
DOI 10.2147/ndt.s91397
Pubmed ID
Authors

Kazuto Oya, Taro Kishi, Nakao Iwata

Abstract

We conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (AOM) for schizophrenia. Randomized controlled trials (RCTs) on AOM, published until June 25, 2015, were retrieved from PubMed, Cochrane, and PsycINFO databases. Relative risk (RR), standardized mean difference (SMD), 95% confidence intervals (95% CIs), and numbers needed to treat/harm (NNT/NNH) were calculated. We identified four relevant RCTs (total n=1,860), two placebo-controlled trials, one noninferiority trial comparing AOM to oral aripiprazole (OA), and one including therapeutic doses of AOM and OA, as well as an AOM dose below therapeutic threshold (control arm). AOM was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS) total scores (SMD =-0.65, 95% CI =-0.90 to -0.41, n=1,126). However, PANSS total scores did not differ significantly between pooled AOM and OA groups. The pooled AOM group showed significantly lower incidence of all-cause discontinuation (RR =0.54, 95% CI =0.41-0.71, n=1,139, NNH =4) and inefficacy (RR =0.28, 95% CI =0.21-0.38, n=1,139, NNH =5) than placebo, but was not superior to placebo regarding discontinuation due to adverse events (AEs) or death. The AOM group exhibited a lower incidence of all-cause discontinuation than OA (RR =0.78, 95% CI =0.64-0.95, n=986, NNH =14), but there were no intergroup differences in discontinuation due to inefficacy, AEs, or death. There were no significant differences in extrapyramidal symptoms scale scores between AOM and placebo or between AOM and OA. AOM resulted in higher weight gain than placebo (SMD =0.41, 95% CI =0.18-0.64, n=734) but lower than OA (SMD =-0.16, 95% CI =-0.29 to -0.02, n=847). AOM has antipsychotic efficacy and low risk of discontinuation due to AEs.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Canada 1 1%
Unknown 67 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 16%
Student > Doctoral Student 10 14%
Other 9 13%
Researcher 8 12%
Student > Postgraduate 6 9%
Other 13 19%
Unknown 12 17%
Readers by discipline Count As %
Medicine and Dentistry 15 22%
Psychology 10 14%
Nursing and Health Professions 6 9%
Neuroscience 5 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Other 12 17%
Unknown 17 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2017.
All research outputs
#4,586,726
of 17,356,510 outputs
Outputs from Neuropsychiatric Disease and Treatment
#611
of 2,663 outputs
Outputs of similar age
#62,132
of 245,290 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#19
of 100 outputs
Altmetric has tracked 17,356,510 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,663 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 245,290 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.